Elicio Therapeutics, Inc. ELTX
We are a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mutant Kirsten rat sarcoma viral oncogene homolog ("mKRAS") - positive pancreatic cancer, colorectal cancer ("CRC"), lung cancer and other mKRAS positive cancers. We intend to build on recent clinical successes in the personalized cancer immunotherapy space to develop effective, off-the-shelf immunotherapies. Our proprietary Amphiphile ("AMP") technology aims to enhance the education, activation and amplification of cancer-specific T cells relative to conventional immunotherapy strategies, with the goal of promoting durable cancer immunosurveillance in patients. Recent advances have identified T cell responses as a key component of effective cancer immunotherapy and we believe our AMP technology can generate robust T cell responses in patients that can potentially translate to meaningful clinical benefit.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $2.3M | $27.5M | $193.0K | — |
| Cost of revenue | — | — | — | $0 | $433.0K | $1.2M | — |
| Gross profit | — | — | — | $2.3M | $27.1M | -$997.0K | — |
| R&D | $24.9M | $33.7M | $23.8M | $18.1M | $48.7M | $39.0M | — |
| SG&A | $12.8M | $11.3M | $11.9M | $5.6M | $18.5M | $18.0M | — |
| Total operating expenses | $37.7M | $45.0M | $35.7M | $23.7M | $67.6M | $58.2M | — |
| Operating income | -$37.7M | -$45.0M | -$35.7M | -$23.7M | -$39.3M | -$55.3M | — |
| Interest expense | $1.1M | $455.0K | $1.1M | $3.6M | $1.8M | $8.8M | — |
| Pre-tax income | -$39.6M | -$51.9M | -$35.2M | -$38.8M | -$54.6M | -$80.1M | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$39.6M | -$51.9M | -$35.2M | -$28.2M | -$54.6M | -$80.1M | — |
| EPS, basic | -2.58 | -4.25 | -6.96 | -89.27 | -1.93 | -5.43 | — |
| EPS, diluted | -2.58 | -4.25 | -6.96 | -89.27 | -1.93 | -5.43 | — |
| Shares, diluted (wtd. avg.) | 15.3M | 12.2M | 9.7M | 315,998 | 28.2M | 14.8M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $18.6M | $17.6M | $14.3M | $8.4M | $10.0M | $34.6M | $5.6M |
| Total current assets | $19.3M | $20.7M | $16.3M | $10.7M | $91.2M | $42.3M | — |
| Property, plant and equipment | $295.0K | $483.0K | $717.0K | $1.1M | $451.0K | $156.0K | — |
| Total assets | $25.9M | $28.2M | $27.1M | $22.7M | $96.5M | $47.3M | — |
| Accounts payable | $672.0K | $1.0M | $4.4M | $2.8M | $4.7M | $5.6M | — |
| Total current liabilities | $8.1M | $11.5M | $9.8M | $6.9M | $11.3M | $107.4M | — |
| Long-term debt | $9.4M | $20.0M | — | — | $0 | $635.0K | — |
| Total liabilities | $24.2M | $39.5M | $15.8M | $13.7M | $15.0M | $137.8M | — |
| Retained earnings | -$233.7M | -$194.1M | -$142.2M | -$107.0M | -$215.1M | -$160.6M | — |
| Total equity | $1.6M | -$11.3M | $11.4M | -$102.1M | -$74.5M | -$90.4M | -$18.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$37.0M | -$37.1M | -$32.7M | -$22.2M | -$52.6M | -$22.9M | — |
| Depreciation and amortisation | $204.0K | $321.0K | $382.0K | $390.0K | $91.0K | $98.0K | — |
| Stock-based compensation | $2.7M | $1.5M | $1.2M | $579.0K | $12.0M | $4.7M | — |
| Capital expenditure | $16.0K | $87.0K | $66.0K | $654.0K | $382.0K | $41.0K | — |
| Investing cash flow | -$16.0K | -$84.0K | -$32.0K | -$654.0K | -$382.0K | -$41.0K | — |
| Financing cash flow | $36.7M | $42.3M | $38.6M | $21.2M | $107.2M | $52.4M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001601485-26-000035.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $193.0K | $27.5M | $2.3M | — | — | — |
| Gross profit | — | -$997.0K | $27.1M | $2.3M | — | — | — |
| Net income | — | -$80.1M | -$54.6M | -$28.2M | -$35.2M | -$51.9M | -$39.6M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event Item 8.01
- Other event Item 8.01
- Results announced Item 2.02
- Material agreement signed Item 1.01
- Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |